Podcasts about Recurrence

See omnystudio.com/listener for privacy information.

No doubt you've heard that certain diets may reduce your recurrence risk, but what about certain nutrients? Currently science doesn't back up the idea that specific nutrient recommendations are the ultimate way to minimize your recurrence risk, however, there is nuance to that. In today's episode I dig into what you need to know about nutrient-dense diets in order to make the best food choices for you!Click here for THE CLARITY SESSIONS packageClick here to get my brand new FREE guide; The 5 Foods Breast Cancer Survivors Worry About Most (and what the science really says)Follow me on Instagram @hormone.breastcancer.dietitian

This is episodes is call the OWCP training session for completing a proper Recurrence of Disability medical narrative. So if you're a treating OWCP provider this is an important episode for you to take notes and if you are an injured federal worker and you think that you have sustained a recurrence of disability and your doctor's reports are not working…or you are receiving the classic, “Claims Examiner excuse of Insufficient evidence” …this is the episode transcript you want to take to your doctor.In the OWCP treating doctor's questions they asked a couple of questions on first, what qualifies for a recurrence of disability and what are the requirements that need to be satisfied for a medical narrative supporting document when a patient is filing a CA-2A form for a recurrence of disability. What do you do when a worker cannot continue to perform their light duty due to increasing pain and dysfunction to their original injury or increasing pain and dysfunction to a new body part that is being aggravated by the inability to use their original body part injury? What is right way to handle this scenario when modified duty has to be changed due to a deterioration in their original condition or an adjacent body part? Is this a recurrence of disability? The answer is yes. For the second part of the OWCP treating physician's question as to what does OWCP claims examiner require from a OWCP treating physician's medical narrative to support a CA-2A recurrence of disability…I will give the exact bulletin points that need to be in the medical narrative. For more information click on the transcript.The podcaster is Dr. Stephen Taylor, OWCP medical-legal consultant & DOL expert for Oberheiden Law Firm.  Dr. Taylor's contact email information is:fedcompconsultants@protonmail If you need a medical provider or assistance with an OWCP /  DOL claim in  Pensacola, Tampa or Jacksonville Florida you can make an appointment to see Dr. Taylor  at the clinic at  FWC Medical Centers or check out the webiste at fedcompconsultants.com To make a consultation with Dr. Taylor  call the clinic at 813-215-4356  in Florida.https://podcast.feedspot.com/workers_compensation_podcasts/?feedid=5557942&_src=f2_featured_emailFor responses email Dr. Taylor at fedcompconsultants@protonmail.comSupport the showFEEDSPOT TOP 10 National Workers Compensation Podcast: https://podcast.feedspot.com/workers_compensation_podcasts/?feedid=5557942&_src=f2_featured_email

Dr. Heon-Jeong Lee (Korea University, Seoul) joins AJP Audio to discuss an app-based intervention designed to help individuals with mood disorders regulate their circadian rhythms to prevent recurrence of mood episodes.  Afterwards, Dr. Ned Kalin will join us again to discuss the rest of the September issue of the Journal, which takes a close look at clinical treatment. 00:44     Findings 01:42     How the app works 03:05     Differences between the app and traditional lifestyle advice 04:14     Ethics surrounding shame treatment arms 05:43     Broader applicability of the intervention 06:50     Limitations 08:19     Immediate clinical implications 09:33     Further research 10:08     Kalin interview 10:27     Yeom et al. 16:02     Schacht et al. 20:31     Khosravani et al. 24:52     Peterson et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

In this podcast, Maryam B. Lustberg from the Smilow Cancer Hospital at Yale, New Haven, CT, USA, Megan-Claire Chase, Life on the Cancer Train, Atlanta, GA, USA, Stacey Tinianov, Advocates for Collaborative Education, Santa Cruz, CA, USA, and Kevin Kalinsky from the Winship Cancer Institute at Emory University, Atlanta, GA, USA discuss the risk of recurrence for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer including early and late risk of recurrence, discuss how risk is assessed, and examine the evolving treatment landscape for reducing risk.. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01241-0. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

In this episode, host Dr. Dan Beswick speaks with Dr. Garret Choby and Dr. Alexandria Harris. They discuss the recently published Original Article: ” Early Versus Late Recurrence in Olfactory Neuroblastoma: A Multi-Institutional Analysis of Predictive Risk Factors.” The full manuscript is available as open access in the International Forum of Allergy and Rhinology. Listen […]

In this episode of The Lead recorded at EHRA, host Christopher Kowalewski, MD, is joined by Tina Baykaner, MD, MPH, and Sanjiv M. Narayan, MD, PhD, FHRS, to discuss the journal article, Relationship Between Time-to-First Atrial Tachyarrhythmia Recurrence and Atrial Fibrillation Burden: Implications for Trial Design. Together, they examine the relationship between time to first atrial tachyarrhythmia recurrence and atrial fibrillation burden and discuss the implications of these measures for clinical trial design. Learning Objectives Review the relationship between time-to-first atrial tachyarrhythmia recurrence and atrial fibrillation burden. Discuss how different measures of atrial fibrillation recurrence and burden may influence the interpretation of clinical trial outcomes. Examine the implications of atrial fibrillation burden and time-to-first recurrence for the design of future atrial fibrillation trials.   Host: Christopher Kowalewski, MD   Guests: Tina Baykaner, MD, MPH and Sanjiv M. Narayan, MD, PhD, FHRS   Disclosures:   C. Kowalewski No relevant disclosures   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   S. Narayan Honoraria/Speaking/Consulting Fee: UpToDate, Inc, LifeSignals, Abbott Medical, TDK Inc. Research: National Institutes for Health Intellectual Property Rights: University of California Regents Stocks – Privately Held: Physcade

Is an elevated prostate-specific antigen (PSA) the beginning or the end of the prostate cancer workup? On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Tarik Benidir to explore the “PSA problem,” explaining why PSA is biologically useful but clinically imprecise, often leading to false positives, unnecessary biopsies, and detection of indolent disease. They discuss a rational, patient-centered approach to elevated PSA, including when to repeat the test, how to interpret results in the context of age, race, family history, and prostate size, and the use of PSA density and age-adjusted norms instead of rigid cutoffs. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported byCleveland Diagnosticshttps://www.isopsa.com/ --- Timestamps 00:00 - Introduction04:03 - Why PSA Can Be Misleading06:43 - Approach to Elevated PSA and Initial Workup09:51 - MRI, PSA Density, and Biomarker Testing14:31 - Guidelines, Diagnostics, and When to Biopsy20:16 - Comparing 4K, IsoPSA, and Other Biomarkers25:23 - Choosing Between Transperineal and Transrectal Biopsy28:42 - Management Considerations for Elderly and Comorbid Patients33:09 - Active Surveillance, Recurrence, and Long-Term Monitoring40:47 - Key Takeaways and Closing Remarks --- More about this episode The conversation highlights the role of reflex biomarkers, MRI scans, and selective biopsy strategies to reduce unnecessary procedures and focus on identifying clinically significant cancers. Dr. Benidir explains how to weigh MRI results, when to use biomarkers, and how to approach decisions in elderly or comorbid patients. They also discuss new biopsy modalities, active surveillance, and future directions for optimizing PSA-based screening and management. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resistant or platinum-refractory disease. The discussion covers systemic therapy options, the role of maintenance therapy with agents like bevacizumab, and the nuanced recommendations for secondary cytoreductive surgery based on mixed clinical trial results. Drs. Lesnock and Bouberhan emphasize the importance of an individualized, multidisciplinary approach to care. As this is a living guideline, they also look ahead to emerging evidence that will shape future updates. Read the full living guideline, "Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0," at www.ascopubs.org/guidelines/systemic-treatment-ovarian-cancer-recurrence" LINK TO FULL TRANSCRIPT

On the heels of consequential primary race results, some of the big winners join the program. Plus, President Trump says that North Korea has 57 powerful nuclear weapons. Also, an experimental vaccine shows promising results for patients with melanoma.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Broadcast from KSQD, Santa Cruz on 8-13-2026: Dr. Dawn opens by reading an anatomy student's elegy to a body donor, reflecting on how modern medical education has moved away from full cadaver dissection toward pre-dissected specimens and models—and what she believes has been lost in that transition. Dr. Dawn dissects how hospital consolidation has become the primary driver of runaway U.S. healthcare costs. She contrasts a $16,000 knee replacement at Catawba Valley Medical Center with a $40,000 procedure for the same Blue Cross Blue Shield plan an hour away at Asheville's Mission Hospital—a facility formed by the 1998 merger of the town's two acute-care hospitals and later acquired by HCA in 2018. Mission now charges 333% of Medicare rates (versus a 280% benchmark), and state inspectors have issued three "immediate jeopardy" findings since HCA's takeover, consistent with academic findings that hospital care quality drops when competition disappears. She notes that CMS-required price disclosures since 2021 finally make this transparent, and calls for regulatory prevention of hospital mergers—especially not-for-profit to for-profit conversions—in single or two-hospital markets. Dr. Dawn analyzes the 3.1% year-over-year drop in prescription drug prices reported through July—the sharpest decline since 1963. She attributes most of it to Biden's 2022 Inflation Reduction Act, which partially rescinded George W. Bush-era Medicare Part D restrictions that had statutorily prohibited price negotiation, saving taxpayers roughly $6 billion in the first six months of implementation. Additional contributors include GLP-1 compounding competition, blockbuster drugs losing exclusivity, and Bureau of Labor Statistics methodology that swaps generics into the price index six months after brand patent expiration. She calls for consumer-facing apps that help patients shop hospital prices the same way they shop cars. Dr. Dawn covers the emerging science of dormant tumor cells—cancer cells that shed from primary tumors even before diagnosis, hide in bone marrow and lymph nodes, and enter a hibernation state (feeding off cellular residue via autophagy) that shields them from chemotherapy targeting rapidly dividing cells. New York researchers have identified proteins by which lung macrophages actively reinforce dormancy, but immune disruption from COVID-19, influenza, aging, and chronic stress can trigger reactivation. She emphasizes lifestyle protection for cancer survivors: minimal alcohol, Mediterranean diet, and five daily cups of green tea for the EGCG dormancy-maintaining effect seen in cell culture. A caller argues for single-payer healthcare and questions whether Medigap insurance is worth $287 monthly. Dr. Dawn explains the math: for a $100,000 hospital bill, 20% coinsurance is $20,000, making the $2,400 annual premium reasonable catastrophic-risk protection—though skipping it is a defensible bet for very low-utilization patients. She notes those whose income drops to Medi-Cal eligibility often end up with better coverage than middle-class seniors. The same caller then presents a differential diagnosis of himself as likely multiple sclerosis based on ChatGPT consultation, describing balance loss requiring hallway wall-guidance, dramatic vision changes, and fasciculations. Dr. Dawn walks through prompt engineering for medical AI: request differential lists ordered by probability of frequency in the population rather than symptom-fit alone. She notes symmetric symptoms argue against MS, suggests checking electrolytes (particularly calcium), and emphasizes that a physical examination should precede imaging to avoid incidentalomas that trigger cascading invasive workups—cautioning that without a primary care doctor, he lacks an advocate within the system.

Love the podcast? Send us a text!What if a blood test could detect signs of breast cancer at the molecular level?Circulating tumor DNA, or ctDNA, is generating growing interest among people diagnosed with breast cancer, particularly those wondering about recurrence, treatment response, and what may be happening in the body before something appears on conventional imaging.One test you may have heard about is Signatera.In this episode of Breast Cancer Conversations, Laura Carfang talks with Shannon and Erin, two women with very different breast cancer experiences who both pursued Signatera testing.Erin was diagnosed with triple-negative breast cancer before her 35th birthday and began exploring Signatera after completing treatment and wondering how she would know if her cancer returned. Shannon was initially diagnosed with DCIS, later developed invasive disease, and is now living with oligometastatic stage IV breast cancer. Her Signatera results became one piece of a much larger diagnostic and monitoring picture.Together, they share the questions, emotions, uncertainty, and conversations with their healthcare teams that came with pursuing ctDNA testing.In this episode:What circulating tumor DNA (ctDNA) isWhat the Signatera test is designed to detectWhy some breast cancer patients are asking about ctDNA testingErin's experience asking her oncologist for Signatera testingShannon's experience with changing Signatera resultsWhat can happen when blood test results and imaging don't seem to tell the same storyRecurrence anxiety and the desire for more informationAdvocating for yourself while still partnering with your medical teamWhat it means to live with oligometastatic breast cancerThe emotional impact of waiting for test resultsThe questions that remain as ctDNA testing continues to evolveThis episode isn't about telling you whether you should—or shouldn't—get Signatera. It's an honest conversation about why patients are interested in this technology, what two women experienced when they pursued it, and why understanding both the possibilities and limitations of emerging testing matters.Important: The experiences shared in this episode are personal stories and should not be interpreted as medical advice. Talk with your oncology team about whether ctDNA testing is appropriate for your individual diagnosis and treatment plan.Support the showListener FeedbackIf this episode resonated with you, we invite you to leave a review on Apple Podcasts or Spotify.You can also click the link in the show notes that says "Love this episode? Send us a text" to share feedback.Messages are completely anonymous.If you would like us to follow up directly, please include your email address in your message so we can respond.Latest News: Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources from SurvivingBReastCancer.org! Become a Breast Cancer Conversations+ Member! Sign Up Now. Enjoying our content? Please consider supporting our work. 

TWiM explains the discovery of avirulent bacterial signature associated with the development of recurrence following colorectal cancer surgery, and phage-derived proteins and conjugates that induce pilus detachment. Take the TWiM Survey

In episode 385 of The Physical Performance Show, host Brad Beer sits down with fellow physiotherapist Lewis Craig for a lateral ankle sprain masterclass. Drawing on material the pair recently presented at a Gold Coast orthopedic evening, Brad and Lewis cover the burden and prevalence of lateral ankle sprains, the three-part clinical assessment process, key differential diagnoses, rehabilitation phases, and preventative strategies including bracing and taping. The episode explores why lateral ankle sprains — despite their reputation as a minor injury — carry a significant risk of chronic ankle instability, and why a thorough, structured assessment is essential to a smooth recovery. Brad and Lewis unpack the different ligament and tendon structures that can be involved, the red flags practitioners need to rule out, the impairment categories drawn from Jay Hertel's model of chronic ankle instability, and how rehabilitation should progress from protection through to return to sport and long-term prevention. Show Sponsor: Pogo Physio also offers online Telehealth Consultations for endurance athletes managing bone, tendon, or joint issues — book online at https://www.pogophysio.com.au. And... PILLAR Performance is leading a new frontier in the sports nutrition industry through micronutrition innovation. Their Performance Health range is designed to support the crucial hours outside of training and racing, helping athletes return to the start line in peak condition. One of their newest releases is Collagen Repair, developed in collaboration with Gelita Laboratories and featuring the clinically trialled collagen peptide TENDOFORT. For 15% off your first purchase, head to pillarperformance.shop or, for North American listeners, thefeed.com and use the code PHYSICALPERFORMANCE at checkout. Pillar Performance continues to lead the way in sports nutrition through micro-nutrition innovation, now expanding into the Performance Health range. One of their newest releases, Collagen Repair, was developed with Gelita Laboratories (Germany) using a clinically trialled collagen peptide (Tendofort) to support tendon and ligament health in conditions like hamstring tendinopathy, Achilles tendonitis, shin splints, and patellofemoral pain. Head to Pogo Physio also offers online Telehealth Consultations for endurance athletes managing bone, tendon, or joint issues — book online at https://www.pillarperformance.shop (or https://www.thefeed.com for North American listeners) and use code PHYSICALPERFORMANCE for 15% off your first purchase.   Partners / links mentioned: Ortho Tools (Cumberland Ankle Instability Tool / CAIT): mentioned in-episode as the online questionnaire resource Contact: Lewis Craig — l.craig@pogophysio.com.au In this episode, you'll hear: Episode context: Lewis Craig's return to the show after being last on around episode 109, and his progress toward finishing his Sports Masters through the University of Queensland The burden of lateral ankle sprains: why they're the most common musculoskeletal injury in sport across field and court sports, contact and non-contact alike Recurrence risk: why roughly 40% of people who sprain their ankle go on to develop chronic instability, and why the one-year mark is a key risk-reduction milestone Early predictors of chronic ankle instability: the Doherty 2016 study on single-leg landing and drop-jump testing at two weeks post-injury The three priorities of assessment: ruling out red flags and fractures, forming an accurate diagnosis, and identifying impairments Screening for fractures: mechanism of injury, the Ottawa ankle rules, weight-bearing ability, and key bony landmarks to palpate Differential diagnosis: ATFL and CFL sprains (70–80% of ankle sprains), peroneal tendon injuries, bifurcate ligament sprains, deltoid ligament tears, syndesmosis injuries, and talar dome injuries Why getting a clear mechanism of injury from the athlete is critical to an accurate diagnosis Identifying impairments: the ROAST consensus and Jay Hertel's updated model of chronic ankle instability — pathomechanical, sensory-perceptual and motor-behavioural impairments Clinical and objective testing: balance progressions, calf raise endurance and strength benchmarks, and power tests including triple hop, crossover hop and timed lateral hop The role of patient-reported outcome tools: the Cumberland Ankle Instability Tool (CAIT) and FAAM, and why they're useful for tracking progress and motivation Rehabilitation framework: protection and appropriate early loading, followed by strength, stability and mobility phases Managing specific injury types: use of moon boots, orthotics, low-dye taping and ASO ankle braces depending on the structures involved Addressing dorsiflexion loss: why regaining ankle range of motion is often one of the hardest parts of rehab, and the Torillin infographic on identifying the source of restriction Late-stage rehab and return-to-sport: hopping, change of direction, and integrating exercises into an athlete's normal training week for ongoing prevention Bracing and taping as secondary/tertiary prevention strategies to reduce recurrence Long-term consequences of poorly managed ankle sprains, including links to post-traumatic osteoarthritis and eventual ankle surgery The biggest mistake athletes make: assuming rehab is "done" once they can run, despite still having deficits in power, change of direction and stability Lewis's top tip: get every ankle sprain properly assessed, no matter how minor Quotes / takeaways: "It's just a simple lateral ankle sprain... and then someone who goes missing for months at a time." "Four out of ten people who have an ankle sprain go on to develop a chronic instability." "The better quality of the assessment, the more likely there's an accurate diagnosis." "It's really hard to sprain your ankle when it's really well strapped or with an appropriate brace." "Once someone gets running... you can run in a straight line really well and have really considerable deficits still." "Get it assessed. Understand what you've done and understand what impairments you might have." Time Stamps: 00:17 – Episode introduction and breakthrough experience 00:23 – Episode 385 introduction: lateral ankle sprain masterclass with Lewis Craig 00:50 – Sponsor: PILLAR Performance and Performance Health 01:15 – Collagen Repair: formulation, TENDOFORT and collagen health 01:44 – 15% PILLAR Performance discount with code PHYSICALPERFORMANCE 02:19 – Welcoming Lewis Craig back to the show 02:48 – Lewis's tenure at Pogo Physio and progress on his Sports Masters at UQ 03:45 – Introducing today's topic: lateral ankle sprains 04:37 – How common and burdensome are lateral ankle sprains? 05:36 – The "she'll be right" attitude and why it's changing 07:02 – Lewis's personal history with recurrent ankle sprains 08:02 – Impact on Lewis's own running and trail running 08:28 – The one-year mark and recurrence risk statistics 09:26 – Predictors of chronic ankle instability: single-leg landing and drop jump 09:53 – The Doherty 2016 study explained 10:51 – The three priorities of assessment 11:21 – Ruling out red flags and fractures 12:45 – Why assessment quality drives rehab outcomes 13:14 – Screening for fractures: mechanism, Ottawa ankle rules, bony landmarks 14:39 – Deciding on imaging: x-ray or MRI 15:06 – Differential diagnosis: the many subcategories of ankle sprain 15:35 – ATFL and CFL: the most common ligament sprains 16:35 – Peroneal tendon injuries 17:04 – Bifurcate ligament sprains 18:04 – Deltoid ligament tears with lateral ankle sprains 18:33 – Syndesmosis injuries and mechanism differences 19:31 – Clinical tests for syndesmosis 20:01 – Talar dome injuries and other easily missed diagnoses 20:30 – Why getting a clear mechanism from the athlete matters 21:29 – Identifying impairments: what it means and why it's important 22:51 – Jay Hertel's model of chronic ankle instability 23:48 – Balancing patient education without causing fear 24:17 – Motor outcomes: strength, power and kinetic chain 24:43 – Assessment time and thoroughness at Pogo Physio 25:08 – Objective testing: dynamometers, balance and calf tests 25:38 – Balance test progressions as return-to-sport criteria 26:37 – Strength testing: inversion, eversion and calf raise endurance 27:07 – Power testing: triple hop, crossover hop and lateral hop tests 27:33 – Using objective markers to guide return-to-sport decisions 28:01 – Patient questionnaires: Cumberland Ankle Instability Tool (CAIT) and FAAM 28:57 – Coping vs non-coping athletes and objective scoring 29:25 – Moving into rehabilitation: individualised management 29:54 – Protection and appropriate early loading 30:20 – Moon boots and protecting specific structures 31:16 – ASO ankle braces for lower-grade sprains 31:45 – The strength, stability, mobility rehab framework 32:14 – Early loading phase: range of motion, balance and strength 32:43 – Addressing dorsiflexion loss 33:13 – The Torillin infographic on restriction sources 33:40 – Progressing balance and strength exercises 34:10 – Preventative efforts and integrating rehab into training 34:40 – Late-stage rehab and return-to-play criteria 35:39 – Bracing and taping to prevent recurrence 36:08 – Long-term consequences: osteoarthritis and ankle surgery risk 37:34 – Lewis's own experience with taping and bracing 38:02 – The biggest mistake athletes make in managing ankle sprains 39:29 – Lewis's top tip: get every ankle sprain assessed 40:27 – Where to reach Lewis Craig for questions 40:52 – Episode close and sponsor reminder 41:20 – Pogo Physio Telehealth Consultations and closing details THE TEAM: Join the The Physical Performance Show LEARNINGS membership through weekly podcasts here: https://www.patreon.com/TPPShow Our goal is to get you back to your Physical Best. Find out more about Telehealth Consultations and book online. Your Hosts:

CardioNerds (Dr. Apoorva Gangavelli, Dr. Rebecca Garber, and Dr. Tina Reddy), discuss pre-pregnancy risk stratification and counseling with Dr. Katy Young across a range of risks.  This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course. Audio editing by CardioNerds intern, Dr. Patrick Pekyi-Boateng. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Notes:  Why is pregnancy considered a “physiologic stress test,” and why does risk extend beyond delivery? Blood volume, heart rate, and cardiac output rise while systemic vascular resistance falls, peaking in the late second/early third trimester; underlying (even undiagnosed) heart disease can be unmasked or worsened. Postpartum (“fourth trimester”) is a high-risk period, not a safe zone – fluid shifts, rising SVR, and bleeding risk can precipitate decompensation in patients with heart failure, pulmonary hypertension, valvular disease, or aortopathy. Adverse pregnancy outcomes (hypertensive disorders, gestational diabetes, preterm birth, fetal growth restriction, peripartum cardiomyopathy) are markers of future cardiovascular risk and warrant long-term preventive follow-up. What is the practical framework for approaching pre-pregnancy cardiovascular risk? Four broad categories: (1) patients who may need cardiac screening before pregnancy, (2) patients needing risk-factor/medication optimization, (3) known cardiovascular disease where pregnancy is reasonable with structured risk stratification, and (4) high-risk disease where pregnancy may need to be delayed, modified by intervention, or discouraged. Testing should be targeted, not blanket – reserved for symptoms, abnormal exam, concerning family history, or reduced functional capacity. How is risk stratified in patients with known cardiovascular disease? Use a combination of tools per 2025 ESC guidelines: mWHO 2.0 (broad maternal risk category), CARPREG II (additional predictors of maternal cardiac events), and ZAHARA (useful in congenital heart disease). Key lesion-specific factors: aortic size/growth, valve severity, ventricular function, symptoms, blood pressure, and family history of dissection. Translate risk into practical terms for patients rather than leading with a numerical score. Which cardiovascular medications require review before conception? ACE inhibitors, ARBs, and ARNIs should be transitioned off before pregnancy; statins, MRAs, and SGLT2 inhibitors also need review. DOACs are contraindicated in pregnancy and lactation; mechanical valve anticoagulation requires individualized shared decision-making, as no strategy is risk-free for mother and fetus. Medication changes are best made proactively, before conception, rather than reactively. This is not an exhaustive list! The medication list needs to be reviewed carefully. Which conditions carry high or prohibitive risk in pregnancy? Pulmonary arterial hypertension, Eisenmenger syndrome, severe ventricular dysfunction, prior peripartum cardiomyopathy with residual LV dysfunction, severe left-sided obstructive valve disease (e.g., severe mitral stenosis), mechanical valves, significant aortopathy, cyanotic congenital heart disease, and Fontan physiology. Common theme: limited cardiovascular reserve and high risk of decompensation, thrombosis, arrhythmia, heart failure, aortic dissection, or death. These patients need expert multidisciplinary evaluation before pregnancy. Severe mitral stenosis is poorly tolerated because tachycardia shortens diastolic filling time and raises left atrial pressure, risking pulmonary edema and decompensation. When should genetic testing or counseling be offered? Consider when a diagnosis may be inherited or affect the patient, pregnancy, or family members: inherited cardiomyopathies, aortopathies, channelopathies, select congenital heart disease, and some pulmonary hypertension syndromes. Recurrence risk of congenital heart disease in offspring is roughly 6-10% when the mother has CHD; fetal echocardiography should be offered. How should contraception be approached in high-risk cardiac patients? Frame contraception as part of the cardiac care and reproductive safety plan to prevent unplanned high-risk pregnancy. Long-acting reversible contraception is often preferred; progestin-only methods are generally safer than estrogen-containing options with thrombosis risk, pulmonary hypertension, or mechanical valves. What are key delivery-planning considerations for cardiac patients? Vaginal delivery is preferred unless there is an obstetric indication for cesarean or a specific cardiac reason (e.g., unstable maternal status, therapeutic INR) to avoid labor. Planning should address delivery location, anesthesia involvement, telemetry needs, fluid management, and postpartum monitoring, clearly communicated across the multidisciplinary team in advance. How should clinicians counsel patients when pregnancy is discouraged but strongly desired? Acknowledge the patient’s goals and the emotional weight of the conversation; separate the goal (family building) from the timeline (safety now vs. after optimization). If pregnancy remains prohibitively risky, discuss alternatives for family building and ensure adequate patient support. What are the key gaps and future directions in cardio-obstetric risk stratification? Current risk tools (mWHO, CARPREG II, ZAHARA) provide common language but do not fully capture functional status, prior pregnancy history, or how risk evolves over time. Future direction: individualized, dynamic risk prediction incorporating imaging, biomarkers, exercise capacity, and social drivers of health, with better long-term links between pregnancy complications and cardiovascular prevention. References 1. European Society of Cardiology. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. 2. Mehta LS, et al. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association. Circulation. 2020;141:e884-e903. PMID: 32362133. doi:https://doi.org/10.1161/CIR.0000000000000772 3. ACOG Practice Bulletin No. 212. Pregnancy and Heart Disease. Obstet Gynecol. 2019;133(5):e320-e356. PMID: 31022123. doi:https://doi.org/10.1097/AOG.0000000000003243

Get your FREE copy of "AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree Most breast cancer survivors finish treatment feeling relieved — but the silent signs of breast cancer recurrence can appear long before your next scan, and most women have no idea what to look for. Your oncologist checks the obvious things. But recurrence doesn't always announce itself with a lump or obvious symptom. Whether you are newly diagnosed, a long-term survivor, or high risk for developing cancer — knowing what your body is trying to tell you between appointments could change everything. So let me show you how it's done. Join the Cancer Freedom Program Apply HERE:https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane PS - Whenever you're ready, here are the 2 best ways I can help you… Get your FREE copy of "AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree   Join the Cancer Freedom Program Apply HERE: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast Let's Connect: Website: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast  

Hyperemesis gravidarum (HG) is far more than morning sickness. In this episode, we break down the science behind severe pregnancy nausea and vomiting, including how it's diagnosed, why it happens, potential genetic causes, treatment options, and what current research says. Dr. Morgan explains the latest evidence surrounding GDF-15, risk factors, medications, IV therapy, nutritional deficiencies, and recovery, while Leah shares her own experience with debilitating pregnancy sickness. Whether you've experienced HG yourself, love someone who has, or simply want to better understand this often misunderstood condition, this episode offers education, compassion, and practical resources.00:00 Introduction02:17 What Is Hyperemesis Gravidarum?03:26 Signs & Diagnostic Criteria05:50 HG vs Severe Morning Sickness07:41 Risk Factors & Who Is Most Likely to Develop HG11:55 Health Risks for Mom18:00 Mental Health & The Emotional Toll23:16 Effects on Baby25:33 What Causes Hyperemesis Gravidarum?27:50 The GDF-15 Gene Explained30:29 Histamine, Mast Cells & Other Possible Causes33:31 Recurrence & Future Pregnancies36:20 Medical Treatment Options42:04 Natural & Integrative Therapies46:21 Chinese Medicine vs Acupuncture50:38 Additional Support Strategies52:58 Recovery After Hyperemesis54:53 Final Takeaways & EncouragementResources From This Episode: Sick - The Battle Against HG - https://www.primevideo.com/detail/0PUSG6EOZI4HTVVAWY18JE66WCHER Foundation https://www.hyperemesis.org/https://herhomeopathy.ca/homeopathy-for-morning-sickness/Gill homeopath - https://consultanthomeopath.com/homeopathySean Chinese Medicine Herbs https://www.folkwiseherbalmedicine.com/

Join our OHSY Hernia team to review the current landscape of bioresorbable meshes and a conversation considering “are they worth it?"Hosts:  Dr. Maggie Bosley - @MBosleyMD Dr. Sean Orenstein - @OrensteinSean Dr. Amber Sandoval Dr. Peter Ferrin Institution: Oregon Health & Science UniversityReferences:- Long-Term, Prospective, Multicenter Study of Poly-4-Hydroxybutyrate Mesh (Phasix Mesh) for Hernia Repair in Cohort at Risk for Complication: 60-Month Follow-Uphttps://pubmed.ncbi.nlm.nih.gov/36102523/- Multicenter, Prospective, Longitudinal Study of the Recurrence, Surgical Site Infection, and Quality of Life After Contaminated Ventral Hernia Repair Using Biosynthetic Absorbable Mesh: The COBRA Studyhttps://pubmed.ncbi.nlm.nih.gov/28009747/- A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)https://pubmed.ncbi.nlm.nih.gov/34976385/- Biosynthetic mesh in hernia repair: A systematic review and meta-analysishttps://journals.lww.com/rhaw/fulltext/2024/07020/biosynthetic_mesh_in_hernia_repair__a_systematic.2.aspxPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

What does the future hold for kidney stone management? In Part 3, David S. Goldfarb explores disparities in care, promising areas of research, and the move towards more personalised approaches to prevention and treatment. He also discusses the impact of climate change on kidney stone risk and shares why he remains optimistic about the future of kidney stone care. Timestamps: 00:46 – Global warming 02:23 – Emerging research/treatments 03:57 – Asymptomatic kidney stones 04:58 – Broad, empiric approach to treatment 08:29 – Occupation as a risk factor for kidney stones 09:56 – Multidisciplinary care 11:51 – Climate change 13:47 – Calcium and kidney stones

Send comments and feedbackAre people who have their first seizure during sleep at greater or lesser risk for future seizures, compared with people who have their first seizure when they're awake? Dr. Laurent Sheybani interviews Dr. Elaine Pang, author of a 2023 paper in Epilepsia that analyzed data from 1,312 adults visiting a first-seizure clinic.This episode also discusses a 2015 evidence-based guideline on managing a first unprovoked seizure in adults. The guideline was developed by the American Academy of Neurology and the American Epilepsy Society. Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.Let us know how we're doing:  info@ilae.orgThe International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Instagram, and LinkedIn.

Circulating tumor DNA (ctDNA), a minimally invasive blood-based biomarker, has emerged as one of the most promising advances in cancer surveillance. Today, we will explore how ctDNA is transforming the management of colorectal cancer and anal squamous cell cancer across the disease continuum—from risk stratification and adjuvant therapy decision-making to surveillance and early detection of recurrence. Through landmark clinical trials, real-world applications, and emerging research, we will examine how ctDNA is helping move cancer care closer to the goal of truly personalized medicine.Hosts: ·       Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center·       Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian·       Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital·       Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer CenterGuests:Dr. Paul Romessor ·      Director of Colorectal and Anal Cancer, Department of Radiation Oncology·      Associate Attending Radiation OncologistMemorial Sloan Kettering Cancer CenterDr. Jeanne Tie ·      Medical Oncologist | Lower GI Unit ·      Lower GI Research Lead ·      Chair | Lower GI Working Party | GI Cancer TrialsPeter MacCallum Cancer Centre Dr. Takayuki Yoshino·      Professor, Global Center of Research Excellence for Advanced Medicine (G-CORE),Keio University School of Medicine·      Executive Advisor to Hospital East Director·      Director, Department of Global Oncology·      Chief, Department of Gastrointestinal OncologyNational Cancer Center Hospital EastLearning Objectives:·      Describe the biological basis and clinical applications of circulating tumor DNA (ctDNA) as a biomarker of minimal residual disease (MRD) in colorectal cancer.·      Interpret the prognostic significance of postoperative and longitudinal ctDNA testing and its role in predicting recurrence risk across stages of colorectal cancer.·      Evaluate evidence from landmark clinical trials, including DYNAMIC and GALAXY, supporting ctDNA-guided treatment de-escalation and escalation strategies in colorectal cancer.·      Discuss emerging applications of ctDNA monitoring in personalized cancer care, including surveillance, treatment response assessment, and future clinical trial directions. References:·      Ando, K. et al. (2026). Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study. Annals of Surgery. https://pubmed.ncbi.nlm.nih.gov/39854721/ (Note: If direct access is limited, the article is available via PMC: PMC12695342)·      Romesser, P. B. et al. (2026). Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38347209/·      Tie, J. et al. (2025). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39943485/·      Tie, J. et al. (2025). Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39974258/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

JJ of Gecko Security and former Disney and Costco CISO Ryan Knisley on why AppSec needs an AI security engineer, not another scanner.DescriptionAppSec has been stuck for years, drowning teams in noisy findings that never told them what was actually exploitable. JJ, co-founder and CEO of Gecko Security, and Ryan Knisley, former CISO at Disney and Costco, join Resilient Cyber to talk about what changes when an AI security engineer reasons across code, infrastructure, and design docs at once. We get into why business logic breaks traditional SAST, why attackers think in graphs while defenders think in lists, why MTTR is a broken metric, how Cal.com went closed source in the AI era, and where AI-driven AppSec consolidation lands over the next two years.Key takeawaysGecko is an AI security engineer, not another scanner. It reasons across code, infrastructure, and documentation, so a finding arrives already mapped to whether it is reachable in production and what data it touches.The context that tells you if a bug matters lives outside the code. Business logic, architecture, and runtime are where exploitability is decided, which is why scanning the code alone floods teams with noise.Business logic is why traditional SAST fails, and why an LLM alone will not fix it. The same endpoint with no auth check is a critical bug in a document store and expected behavior in a social app, and only design docs and architecture tell the two apart.Attackers think in graphs while defenders think in lists. A critical with a compensating control may not matter, while ten lows chained together can be the thing that actually reaches the asset you care about.Exploit development is being commoditized. JJ describes a near future where the whole internet becomes one big bug bounty scope with agents running campaign-level attacks, so the old severity-ranking lens no longer holds.Fix the class, not the ticket. Rather than patching bugs one by one, Gecko traces groups of findings back to the design decision that created them and eliminates every variant so the same issue never returns.MTTR is a broken metric. A variant of last week's bug returns with a fresh clock, so teams close tickets to look healthy while risk stays flat, which is why Gecko measures recurrence rate instead.Cal.com shows where open source is heading. After AI coding pushed its pull requests from about 30 a day to 100 with a one-person security team, being open source flipped from an advantage to a liability, so it went closed source and replaced four tools with one.Tool consolidation is a risk decision, not a cost exercise. Ryan's shiny object problem leaves teams stacking scanners nobody can fully staff, and collapsing the stack lets you cross-train people and reduce real complexity.The finding layer collapses, and human judgment moves up. When finding and fixing get cheap, the scarce work becomes deciding what is correct, whether to accept a risk on purpose, and owning the design decision for a whole class of bugs.Chapters00:00 Meet JJ and Ryan02:46 Why Gecko is an AI security engineer, not another scanner05:07 The trend of agentic and headless security tools05:53 Why business logic breaks traditional SAST06:27 The no-auth endpoint example and context outside the code09:06 Attackers think in graphs, defenders think in lists11:02 Commoditized exploit dev and the internet as one bug bounty13:55 Shift left and why MTTR is a broken metric15:07 Eliminating entire classes of vulnerabilities15:51 Recurrence rate and avoiding risky refactors18:22 The Cal.com case study and open source going closed20:48 Consolidation and the shiny object problem in security22:40 Where AI-driven AppSec lands in two years27:12 What it takes to trust an AI security engineer28:57 Where to find Gecko and the Black Hat talk

Get your FREE copy of "Ultimate Anti-Cancer Food Guide" here: https://cancerfreedomprogram.com/ultimateanticancer Most survivors are doing everything right to prevent cancer recurrence — except for the two ingredients sitting in plain sight. The ones most doctors never bring up could be the difference between staying free and starting over. Here's the gap: cancer care focuses almost entirely on treatment and screening, but rarely on what ends up on your plate every single day. These two ingredients are simple, affordable, and easy to work in. So let me show you how it's done. Join the Cancer Freedom Program Apply HERE: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast   #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane PS - Whenever you're ready, here are the 2 best ways I can help you… Get your FREE copy of "Ultimate Anti-Cancer Food Guide" here: https://cancerfreedomprogram.com/ultimateanticancer Join the Cancer Freedom Program Apply HERE: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast Let's Connect: Website: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast  

BUFFALO, NY – June 15, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 5, 2026, titled “A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.” The study was led by first author Emily Bivens and corresponding author Mayumi Nakagawa from the University of Arkansas for Medical Sciences, Little Rock. Head and neck squamous cell carcinoma (HNSCC) remains a major clinical challenge. Even after surgery, radiation, and chemotherapy successfully eliminate detectable disease, many patients experience recurrence within the following years. Researchers have therefore been exploring whether immunotherapy-based approaches can help strengthen anti-tumor immune responses and reduce the risk of cancer returning. In this study, investigators evaluated PepCan, an experimental therapeutic vaccine designed to stimulate immune responses against human papillomavirus type 16 (HPV 16). Unlike preventive HPV vaccines that aim to stop infection before it occurs, therapeutic vaccines are intended to activate the immune system against existing HPV-related disease. PepCan contains four HPV 16 E6 peptides combined with a Candida-derived immune-stimulating adjuvant. Full press release - https://www.oncotarget.net/2026/06/15/hpv-therapeutic-vaccine-shows-safety-but-uncertain-benefit-in-preventing-head-and-neck-cancer-recurrence/ DOI - https://doi.org/10.18632/oncotarget.28892 Correspondence to - Mayumi Nakagawa - mnakagawa@uams.edu Abstract video - https://www.youtube.com/watch?v=oh0MNrrPGhw Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28892 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, human papillomavirus, head and neck cancer, therapeutic vaccine, adjuvant, clinical trial To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Liao breaks down Lions injuries The Daily DLP welcomes Dr. Jimmy Liao to the show to talk about the Lions injuries and recoveries. The biggest name is Kerby Joseph, as the safety is dealing with a troublesome knee injury. Dr. Liao breaks down what options the Lions have with the All-Pro, noting that holding him out from the offseason workouts is medically necessary. Brian Branch's Achilles and what defense demands Brian Branch tore his Achilles on December 4, 2025. A comparison was made to another high-profile Achilles tear, San Francisco TE George Kittle, on January 11. The positions are different. Defense is reactive. The secondary lives in backpedals and sudden bursts. That movement is the top mechanism for Achilles injury. It can slow the return for a defensive back compared with an offensive player who can script his steps. Recent rehab clips showed light treadmill jogging. No hard sprinting. No jumping. No cutting. He is roughly six months out and not ahead of schedule on visible benchmarks. The earlier expectation hovered around midseason. There is no clear evidence to move that up. Sam LaPorta's back: progress now, recurrence is the concern Sam LaPorta appeared at OTAs. He caught passes. He is not full go, but the trend is positive. A herniated disc can flare with accumulated contact. Blocking can hyperextend the back. Last season's issue was not a single moment. It built over time. There is a good chance he is ready for Week 1. The question is durability over months, not days. Recurrence risk sits in the background and will only be answered by workload. Depth chart ripple effects: OL Lisfranc, ACL note, and return-game risk An offensive lineman, Ben Bartch, is recovering from Lisfranc surgery. He has not appeared in the first two weeks of OTAs. Lisfranc injuries live in a small, tricky part of the midfoot. Outcomes can be uncertain, especially for a big body that must anchor and drive. The Lions guaranteed $330,000 on his one-year deal, a sign of confidence at signing, but the absence raises flags until he is on the field. Kendrick Law suffered an ACL tear. Standard ACL recoveries are reliable. Barring complications, the expectation is a full return for 2026 OTAs. Safety Dan Jackson has been present in team photos during OTAs. Last year's leg issue lacked detail, but current participation eases concern. Kickoff changes have pushed return rates above 70 percent. Depth at returner matters. The play remains risky for the returner, even as it gets safer for blockers and coverage. Recent examples include a neck scare for Kalif Raymond and a fractured ankle for James Houston on a high-speed collision. Minicamp next week will sharpen clarity across the Detroit Lions depth chart. #detroitlions #lions #detroitlionspodcast #injuries #recoverytimeline #kerbyjoseph #brianbranch #samlaporta #georgekittle #lisfranc #benbartch #danjackson Learn more about your ad choices. Visit megaphone.fm/adchoices

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Get your FREE copy of "AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree Your doctor says your labs look "normal" — but normal is not the same as optimal when you're trying to prevent a cancer recurrence. There are specific blood work markers that can give you an early warning sign that cancer is trying to come back — and most conventional doctors never even order them.  So let me show you how it's done. Join the Cancer Freedom Program Apply HERE:https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane PS - Whenever you're ready, here are the 2 best ways I can help you…  Get your FREE copy of "AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree  Join the Cancer Freedom Program Apply HERE:https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast Let's Connect: Website: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast  

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

Where you are right now is not random—it's intentional, and it's revealing. In this episode, we dive into the affirmation “I am exactly where I'm supposed to be” and what it truly means to embody it, even when life doesn't look how you expected.I share how this affirmation has shaped my perspective, how to start seeing your current reality as valuable data instead of a setback, and why every situation—good or challenging—is working in your favor. We also break down the Law of Recurrence and how patterns in your life are not punishments, but teachers guiding you toward growth and alignment.If you're in a season that feels confusing, uncomfortable, or unclear, this episode will help you ground yourself, find power in the present moment, and start consciously shifting your reality. You'll walk away with a mindset that allows you to honor where you are while confidently creating what's next.✨ Theresa's Tools & Links :Affirmation Academywww.theresacesare.comMy Affirmation Card DeckJoin my newsletter for exclusive content & mindset toolsFollow me on Instagram:Personal page @iamtheresacesareAffirmation Babe @iamtheaffirmationbabeSupport the show

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Orforglipron for maintenance of body weight reduction  - Nature Medicine2026. Discussion by:Guest:Joe Gonella, MD Resident - Abington Family Medicine Residency Program Jefferson Health2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026.  Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.   NEJM 2026 Discussion by:Guest:Alex Sauer, MD Resident - Abington Family Medicine Residency ProgramJefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Results from the OPTIMA trial suggest that people with early-stage hormone receptor-positive, HER2-negative breast cancer that seems to have a high risk of recurrence based on clinical features — like a high number of positive lymph nodes — may be able to safely skip chemotherapy if they have a low Prosigna risk of recurrence score. The findings were presented at the 2026 American Society of Clinical Oncology Annual Meeting. Iain MacPherson, professor of breast oncology at the University of Glasgow, was chief investigator of the study. Listen to the episode to hear Dr. MacPherson explain: the design and results of the OPTIMA study why he thinks the trial results are groundbreaking whether or not the results apply to men with this type of breast cancer

Sent us a text, you dicks!!IT'S BAAAAAAAAAAACK!!!!Your thought we were done with the sonnet episodes, didn't you?? NO, DEAR LISTENERS!!!! (After all, there are 154 of them!!!)And this time, we have our dear friend (and one of the top fans of the pod!!) Brian Linden with us!! Brian has chosen Sonnet 19 to perform and discuss, and we are tickled pink!!!Strap in and get ready!!!To send us an email - please do, we truly want to hear from you!!! - write us at: thebardcastyoudick@gmail.com To support us (by giving us money - we're a 501C3 Non-Profit - helllloooooo, tax deductible donation!!!) - per episode if you like! On Patreon, go here:  https://www.patreon.com/user?u=35662364&fan_landing=trueOr on Paypal:https://www.paypal.com/donate/?hosted_button_id=8KTK7CATJSRYJWe also take cash!   ;DTo visit our website, go here:https://www.thebardcastyoudick.comTo donate to an awesome charity, go here:https://actorsfund.org/help-our-entertainment-communiity-covid-19-emergency-reliefLike us? Don't have any extra moolah? We get it! Still love us and want to support us??   Then leave us a five-star rating AND a review wherever you get your podcasts!!Support the show

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Peter Carroll discusses biochemical recurrence. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41556]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Peter Carroll discusses biochemical recurrence. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41556]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Peter Carroll discusses biochemical recurrence. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41556]

If you've ever laid awake at 2 or 3 in the morning wondering, "What if it comes back?"...this episode is for you. You are not alone, and you are not weak. In fact, nearly 6 in 10 cancer survivors report a fear of recurrence, and among young survivors that number jumps to 88%. It's the most common unmet need in survivorship...and almost no one talks about it openly. In this episode, Jen shares honestly where she is five years after her breast cancer diagnosis, what the fear of recurrence used to look like, and what's changed. Spoiler: the fear didn't disappear, but it's no longer running the show. What you'll learn in this episode: Why fear of recurrence is the most common (and most under-discussed) part of survivorship The research and statistics behind fear of recurrence in cancer survivors How to build your own trigger inventory so you stop getting ambushed The lifestyle, environmental, and spiritual shifts that helped Jen take her power back The one mindset shift that changes everything: from "What if it comes back?" to "If it comes back, here's what I do" Small, doable practices for when the fear shows up at 2 AM Why naming the fear out loud takes its power away How to choose the one person you can be totally honest with Key moments / chapter markers: (00:03) Why this thought is the most normal thing in the world (01:00) The research: 6 in 10 survivors carry this — and women carry it more (02:00) Building your trigger inventory: scans, anniversaries, Facebook memories, headlines (04:00) The work that changed everything — diet, environment, toxins, lifestyle (07:00) Becoming more spiritual and making peace with the unknown (09:30) Why breast cancer treatment in 2026 is night-and-day from 5–10 years ago (10:30) The shift: from "What if?" to "If it does, here's what I'll do" (11:30) Three small things to try when the fear shows up (14:00) The truth: the fear doesn't leave, but it stops being the loudest voice Connect with Jen: Community: Not Today Cancer — The Inner Circle GET BrocElite: Mara Labs supplements - Use code NotTodayCancer for 20% off Instagram: https://www.instagram.com/jendelvaux/ Email me: coachjennyd@gmail.com A gentle reminder: This episode is not medical advice and not a prescription. It's one survivor's story and the tools that have helped her. Always work with your own care team on what's right for you.  

A casual night watching sports, a quick breast self-exam, and a lump that did not belong there. Faced with no insurance and four months of not knowing what to do, Felicia Kent walked into a neighborhood clinic, received a referral to The Rose, and heard the three words that changed everything: you have cancer. In this episode, she talks about choosing a treatment center, using research and strict adherence to medication to blunt chemo side effects, and learning to live with radiation fatigue, lymphedema, neuropathy, and a body that will never be the same. She also shares how faith, a determined daughter, an emotional support dog, and a calling to serve other survivors led her to start a nonprofit, finish her psychology degree, and focus on practical support and early mammograms in the African American community. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. How did Felicia find her lump and what kept her from seeking help immediately? 2. How does someone without insurance get from a neighborhood clinic to The Rose for diagnostic care? 3. What does it feel like to hear “you have cancer,” and how did Felicia share that news with her family? 4. How did she choose a treatment center and manage chemo, surgery, and radiation side effects day to day? 5. What practical strategies helped her reduce chemo side effects like nausea, mouth sores, and nosebleeds? 6. How is she now supporting other patients through a nonprofit, church outreach, and peer-to-peer work? 7. Why are mindset, faith, and social support so critical during and after breast cancer treatment? 8. How is she raising awareness about mammograms and access within the African American community? 9. What long-term issues like lymphedema, neuropathy, and fear of recurrence does she still live with? 10. How does an emotional support dog, movement, and counseling help manage post-treatment anxiety? Timestamped Overview 00:00 Episode opens, Felicia’s story as an uninsured survivor who reached The Rose through a neighborhood clinic is introduced.01:20 Guest host Shannon McNair welcomes Felicia and asks how she discovered her lump and used self-exams.01:40 Felicia describes finding the lump by chance, lacking insurance, and remembering The Rose from boutique work.02:40 She visits a nearby clinic, receives an immediate referral to The Rose, and later credits the team with saving her life.04:30 Telling her sister, leaning on prayer, and deciding early to be a testimony for others facing cancer.06:20 What she wishes she had known about treatment, side effects, and why she followed medication instructions exactly.07:40 Lesser-discussed chemo and radiation side effects like mouth sores, nosebleeds, and fluid issues, and how she managed them.08:40 Birth of her nonprofit work, finishing a psychology degree during treatment, and pursuing community health worker training.09:50 Current advocacy: blogs, peer-to-peer conversations, holiday outreach, and small gifts to patients during treatment.10:40 Common questions she hears about insurance, alternatives, and staying positive through harsh treatments.12:10 How to support someone with cancer when you do not know what to say, including quiet presence and simple statements of love.13:40 Encouraging friends and family to show up with meals, learning, and practical help, while survivors learn to express what they need.16:30 Holiday and year-round programs for patients, including Christmas deliveries, Valentine outreach, and church-based change collections for donations to The Rose.19:10 Focus on education and early detection in the African American community, especially for younger women and those wary of treatment.20:30 Balancing chemo, lumpectomy, graduation, radiation, and then managing fluid buildup and other late effects.23:50 How an emotional support dog, daily walks, and therapy help manage anxiety and fear of recurrence after treatment.26:00 Decision to delay reconstruction, experiences losing a young niece and a church member to breast cancer, and why that fuels her advocacy.27:20 She reflects on cancer as an ongoing learning experience, the importance of mental health care, and continuing in support groups.See omnystudio.com/listener for privacy information.

Previous literature has demonstrated that an increased number of preoperative anterior shoulder instability episodes is associated with recurrent anterior shoulder instability after arthroscopic Bankart repair (ABR). However, a threshold for the number of preoperative instability episodes that increases the risk of recurrent anterior shoulder instability is not well established.   A threshold of ≥2 preoperative anterior shoulder instability episodes best predicted recurrent anterior shoulder instability after ABR. Stratification beyond 1 versus ≥2 preoperative anterior shoulder instability episodes did not increase predictive ability. This finding may help surgeons to counsel patients and consider earlier surgical stabilization in those who have sustained anterior shoulder instability episodes.   Click here to read the article.

Welcome to the first episode in this week's triple-header of late-breaking clinical trial coverage from Heart Rhythm 2026 in Chicago. In this episode Melissa E. Middeldorp, MPH, PhD from the Digital Education Committee sits down with David H. Birnie, MD and T. Jared Bunch, MD, FHRS to talk through this exciting late breaker. This late-breaking substudy of the ALONE-AF trial presented at Heart Rhythm 2026 evaluated whether discontinuing oral anticoagulation (OAC) after successful atrial fibrillation ablation impacts cognitive function in patients without long-term recurrence. The findings suggest that stopping OAC approximately one year post-ablation does not adversely affect cognitive outcomes, with cognitive scores improving similarly in both discontinuation and continuation groups among patients who remained arrhythmia-free. These results support the potential safety of OAC discontinuation in selected patients, while addressing an important gap in post-ablation management. Learning Objectives Understand the clinical rationale and current uncertainty surrounding continuation versus discontinuation of oral anticoagulation after successful AF ablation. Evaluate the impact of anticoagulation discontinuation on cognitive function in patients without recurrent atrial fibrillation. Apply emerging evidence from ALONE-AF and related studies to inform individualized decision-making on long-term anticoagulation management post-ablation.   Podcast Contributors Melissa E. Middeldorp, MPH, PhD David H. Birnie, MD T. Jared Bunch, MD, FHRS   Contributor Information: M. Middeldorp Nothing to disclose. D. Birnie Nothing to disclose.  T.J. Bunch • Honoraria/Speaking/Teaching/Consulting: Heart Rhythm Society, Pfizer  

In this episode, Eric and Jeff hang out with Perry Maughmer—a returning guest and one of their all-time favorite people—for an honest, practical (and sometimes funny) discussion about what it really means to grow as a person and a leader.What's Inside This Episode?Perry's New Book: Why He Wrote It for Himself - Perry tells us all about his newest book, The Recurrence Effect. But get this—he wrote it for himself first, doesn't care if it sells, and purposely didn't jam it with easy answers. His goal? Help you realize you have what you need already inside, even if that means sitting with the messy stuff and more ambiguity than you're used to.Why Copying Someone Else's Life Hacks Never Works - Ever get sucked into those “guaranteed” success frameworks online? Perry has zero time for that. He explains that just because a system or trick worked for one person doesn't mean it'll fit you. It's like wearing someone else's custom suit—a weird fit at best!Leadership: It's a Doing Thing, Not a Title - There's a super cool take here—Perry doesn't think “leader” should be a title. It should be about what you do, not who you are. The best leaders care about people, not KPIs. Results follow from that—not the other way around!How Companies Get People Development Wrong - Why do so many places take their top performer and make them a manager? Spoiler: it almost never works out how they hope. There's some real talk about how real people development takes YEARS of intentional change. No overnight hacks here.Curiosity vs. Judgment (and Why Saying "I Don't Know" Rocks) - Perry drops wisdom about choosing curiosity over judgment at work. Admitting you don't know everything actually makes you a better teammate and leader. Seriously—being curious opens up so many more possibilities.AI Is Eating Up Technical Skills—Now What? - Worried robots are taking your job? Perry says the real winners will be people who love to learn, not just people with mad technical skills. The key is staying adaptable and being comfortable with change and surprise.The Real Treasure is Inside - All the themes circle back to one core idea: stop forever searching for solutions outside yourself. Take ownership, look inward (even if it's scary), and realize you have what you need to keep growing and leading. It's not a quick fix, but it's more real.Real Moments & LaughsKicking off with some Bigfoot and Canadian toque jokesHonest opinions about why editing a book is “horrendous” and marketing can feel fakeWhy company learning should be voluntary and nobody should get dinged for “opting out”Featured Book:The Recurrence Effect by Perry Maughmer – Find it on Amazon and wherever you get your books.Get More from Perry:Podcast (he's starting it up again—no set routine, just genuine thoughts when he has them)Substack newsletter: “Inside the Return”Join the Conversation!Had any “aha!” moments? Ever felt like you were supposed to have life all figured out—when you really just needed some new questions? We want to hear from you:Have you ever chased outside answers when you maybe needed to look inside?How are you handling all the changes with tech and work?In each episode, Jeff and Eric will talk about what emotional intelligence, or understanding your emotions, can do for you in your daily and work life. For more information, contact Eric or Jeff at info@spiritofeq.com, or go to their website, Spirit of EQ.You can follow The Spirit of EQ Podcast on Apple Podcasts, Android, or on your favorite podcast player.New episodes are available on the 2nd and 4th Wednesdays every month!Please review our podcast on iTunes. Click on the link for an easy, step-by-step tutorial.Music from Uppbeathttps://uppbeat.io/t/roo-walker/deeperLicense code: PEYKDJHQNGSZXDUEhttps://creativecommons.org/licenses/by-nd/4.0/We hope you enjoy the podcast. Hopefully, you're tuning in on a regular basis. We'd love it if you would give us a great review on whatever platform you're listening to the podcast. It's so appreciative and helps us as we try to get more exposure for the work we do and the episodes that we publish. We're grateful to you as a listener. Secondly, our content is for educational purposes only. It's not intended by any stretch to diagnose or treat anything that may be occurring in your life or anyone else's life that you may be connected to through the podcast. And as always, we look forward to the next time that we're together. Take care.Spirit of EQMentioned in this episode:Thanks for listening to Spirit of EQThis podcast was created to be a tool to primarily help you to discover and grow your EQ. Science and our own lived experiences confirm that the better we are at managing our emotions, the better we're going to be at making decisions. Which leads to a better life. And that's something we all want. We're glad that you've taken the time today to listen. We hope that something you hear will lead to a breakthrough. We'd really appreciate a review on your podcast platform. Please leave some comments about what you heard today, as well as follow and subscribe to the podcast. That way, you won't miss a single episode as we continue this journey.

Our episode discussion includes comparing different Popemobiles (thanks Sheldon for the Pope fun fact!), what we would have done if we were Leonard, the bullying situations at our own schools, a better solution than letting Jimmy sleep on the couch, and more!Download hereRunning time: 1:22:35, 59.6 MB

Are you confident in identifying the risk for recurrence in early-stage HR-positive, HER2-negative breast cancer? Credit available for this activity expires: [04/21/27] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?ecd=bdc_podcast_libsyn_mscpedu

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Shengwen Calvin Li and Hrishi Krishna Srinagesh on their latest articles published in Blood. Dr. Li discusses "Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21". The study identifies reproducible abnormalities in progenitor expansion and increased apoptosis of polyploid megakaryocytes, and they propose a novel mechanism in which centrosomal over-expression of ANKRD26 drives polyploid megakaryocyte apoptosis through JUNB-mediated induction of p21 transcription. Dr. Srinagesh discusses "Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL" in which data collected by the Real-World Outcomes Collaborative of CAR-T in Adult ALL consortium showed that prior nonresponse to blinatumomab was associated with inferior survival after brexucabtagene in comparison to blinatumomab-naïve patients. Early CAR-T responses were uniformly high regardless of prior exposure or response. This highlights that resistance to blinatumomab may identify patients at higher risk of post–CAR T relapse despite excellent initial responses.

Sponsor-Stark Real-estate-[https://www.starkrealestatemi.com/](https://www.starkrealestatemi.com/)Get Episodes early-https://www.patreon.com/cw/TheMetalManiacsPodcast Welcome back to Metal Maniacs, hosted by Jay Ingersoll and Modd. In the 26th installment of our Reaction Series, we dive into a stacked batch of underground heavy music—alt metal, melodic metalcore, modern metalcore, groove metal, hard rock/metal, sludge/doom, and more.This episode features reactions to:Absent Light Arena — a two-piece project working between Australia & Sweden, blending atmospheric alt metal and melodic metalcore with cinematic electronics (debut album Fear, Doubt and Disbelief).Recurrence — heavy Michigan-adjacent heat with the album Art of Survival featuring guest talent including Björn “Speed” Strid (Soilwork), Peter Wichers (ex-Soilwork), and Per Nilsson (Scar Symmetry).Elijah Kinney — Detroit-area bassist/solo artist bringing sharp modern heavy songwriting and production (including “S.O.S” and the upcoming EP War of Submission).Mortal Draw — brand new band from Northwest Indiana dropping their first release.Terror Garden — Long Island hard rock/metal with “Supermodel Virus” and a new EP on the horizon.Devilz By Definition — groove metal for fans of Lamb of God, Pantera, Machine Head, including the intense “Angel Warfare.”Sod The Earth — Grand Rapids “dadcore” sludge/doom with Enter The Den (yes, it's as unhinged as it sounds).Xemaulc'tha — dark, story-driven heavy metal with “She Walks at Night” (feat. Rikk Hernandez).If you're into discovering new metal bands, underground metalcore, and heavy music that doesn't sound like everyone else—this one's for you.Like, subscribe/follow, and drop a comment telling us which band you want us to feature next.Band LinksAbsent Light Arena: Spotify | YouTube | Instagram | LinktreeRecurrence: Art of Survival (Spotify) | “Remember Who the Enemy Is” (YouTube) | About | Website | YouTube | LinktreeElijah Kinney: Website | YouTube | “S.O.S” Lyric VideoMortal Draw: Linktree | YouTubeTerror Garden: “Supermodel Virus” (Official Video) | LinktreeDevilz By Definition: Website | YouTube | SpotifySod The Earth: Instagram | Enter The Den (Spotify) | “The 10th Frame” (Spotify)Xemaulc'tha: “She Walks at Night” (YouTube) | Spotify | Apple MusicFollow Us-https://linktr.ee/metalmaniacsmi

In this new episode of Speaking of SurgOnc, Dr. Rick Greene & Dr. Mohammed Farooq discuss the article "Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy", from the January 2026 issue of the Annals of Surgical Oncology.    

In this episode, we break down a major factor in treating SIBO and preventing recurrence: biofilm disruption. You'll learn how to identify the telltale signs of biofilms, the steps to our proven treatment protocol, and discover the dietary and supplement strategies that support lasting gut recovery. Our approach is backed by our recently published study, Biofilm Disruption Enhances Antimicrobial Therapy for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth. Read the full findings here:https://pubmed.ncbi.nlm.nih.gov/41394228/.    If you've struggled with recurring SIBO and felt like nothing works, this episode will guide you to effective solutions.  

In episode 520 astrologer Nick Dagan Best joins me for a live workshop where we interviewed five listeners who shared stories about how recurrence transits coincided with important moments in their lives. This is a follow-up to our original episode on recurrence transits from November 2025, where we first introduced the concept of tracking when planetary aspects in the sky repeat specific aspect configurations from your birth chart. While our initial discussion focused largely on celebrity charts to illustrate the theory, for this episode we wanted to demonstrate how this technique manifests in practice by interviewing several patrons who generously shared their personal stories. During the show, we speak with five listeners who walk us through their chronologies to show how these transits coincided with major life events. We examine a wide variety of planetary combinations, including Mars-Saturn, Mars-Uranus, and Venus-Jupiter alignments. The examples illustrate how the repetition of a natal aspect can trigger pivotal turning points involving career changes, relationships, accidents, and even multi-generational family patterns. What becomes clear through these interviews is how the recurrence of a natal aspect often coincides with events that are thematically consistent with the original promise of the birth chart, sometimes playing out as literal repetitions of the past or as significant evolutions of a personal narrative. We also discuss some of the technical nuances of working with recurrence transits, such as the importance of phase relationships, and how to track these cycles using the search tools available on Astro-Seek. This episode serves as a practical demonstration of how to research and apply this technique to gain a deeper understanding of your own biography and the timing of major life events. Nick's Website https://www.nickdaganbestastrologer.com Timestamps 00:00:00 Introduction00:04:48 How to look up recurrence transits in your chart00:12:58 Ginger: Mars-Saturn Recurrence00:34:34 Jacqueline: Venus-Jupiter & Mars-Saturn Recurrences01:01:44 Karen: Jupiter trine Uranus Recurrence01:12:04 Lauren: Venus-Mars and Mars-Saturn Squares01:32:41 Connie: Venus-Jupiter Square Recurrence01:48:07 Q&A and Final Thoughts01:56:03 Credits Watch the Video Version of This Episode https://www.youtube.com/watch?v=cPCr7-e8vtI - Listen to the Audio Version of This Episode Listen to the audio version of this episode or download it as an MP3: